[go: up one dir, main page]

UA93201C2 - АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1 - Google Patents

АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1

Info

Publication number
UA93201C2
UA93201C2 UAA200711364A UAA200711364A UA93201C2 UA 93201 C2 UA93201 C2 UA 93201C2 UA A200711364 A UAA200711364 A UA A200711364A UA A200711364 A UAA200711364 A UA A200711364A UA 93201 C2 UA93201 C2 UA 93201C2
Authority
UA
Ukraine
Prior art keywords
antibody
human tgf
tgf beta
neutralizing human
antibody neutralizing
Prior art date
Application number
UAA200711364A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джулиан Дейвис
Крейг Дуейн Дикинсон
Лиха Ханг
Брайан Эдвард Джоунз
Дейвид Метью Маквис
Скотт Уильям Роулинсон
Инь Тань
Питер Эдвард Валльянкорт
Джеффри Дин Уоткинс
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of UA93201C2 publication Critical patent/UA93201C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

Изобретение относится к антителу или его антигенсвязующему фрагменту, который нейтрализует человеческий TGF-β1 и имеет Кменьше 40 пМ. Изобретение также относится к фармацевтической композиции, которая содержит данное антитело, а также к применению заявленного антитела для изготовления лекарственного средства для лечения фиброзного заболевания у человека, хронического заболевания почек у человека, а также к применению антитела в комбинации с ингибитором ацетилхолинестеразы.
UAA200711364A 2005-04-22 2006-04-20 АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1 UA93201C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67408205P 2005-04-22 2005-04-22

Publications (1)

Publication Number Publication Date
UA93201C2 true UA93201C2 (ru) 2011-01-25

Family

ID=37192643

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200711364A UA93201C2 (ru) 2005-04-22 2006-04-20 АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1

Country Status (23)

Country Link
US (2) US7619069B2 (ru)
EP (1) EP1874818B1 (ru)
JP (1) JP5070200B2 (ru)
KR (1) KR100978684B1 (ru)
CN (1) CN101163719A (ru)
AT (1) ATE505489T1 (ru)
AU (1) AU2006240056B2 (ru)
BR (1) BRPI0608376A8 (ru)
CA (1) CA2607448C (ru)
CY (1) CY1111518T1 (ru)
DE (1) DE602006021292D1 (ru)
DK (1) DK1874818T3 (ru)
EA (1) EA016038B1 (ru)
ES (1) ES2361269T3 (ru)
HR (1) HRP20110334T1 (ru)
IL (1) IL186775A (ru)
NO (1) NO20076003L (ru)
PL (1) PL1874818T3 (ru)
PT (1) PT1874818E (ru)
RS (1) RS51845B (ru)
SI (1) SI1874818T1 (ru)
UA (1) UA93201C2 (ru)
WO (1) WO2006116002A2 (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334330A4 (en) * 2008-09-29 2013-05-15 Janssen Biotech Inc ANTI-CD147 ANTIBODIES, METHODS, AND USES
CN104034901A (zh) * 2008-11-22 2014-09-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
WO2010077831A1 (en) * 2008-12-16 2010-07-08 Tod Lauerman Targeted cytokine for treatment of diseases
CA2749115C (en) 2009-01-09 2022-06-21 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
WO2012129330A1 (en) 2011-03-23 2012-09-27 Option Pharmaceutical, Llc Targeted cytokine for treatment of musculoskeletal diseases
DK2714735T3 (da) * 2011-06-03 2021-10-18 Xoma Technology Ltd Antistoffer, der er specifikke for TGF-beta
JP6431372B2 (ja) 2011-10-25 2018-11-28 プロシーナ バイオサイエンシーズ リミテッド 抗体製剤および方法
MX2014010839A (es) 2012-03-08 2016-07-06 Selig Sealing Products Inc Sello de recipiente con componente de seguridad protegido y lengüeta de remocion.
EP2822592B1 (en) * 2012-03-08 2018-08-15 Ludwig Institute for Cancer Research Limited Tgf- 1 specific antibodies and methods and uses thereof
MX362456B (es) 2012-08-24 2019-01-18 Univ California Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EP3816625B1 (en) 2013-05-06 2025-09-17 Scholar Rock, Inc. Compositions and methods for growth factor modulation
KR102738546B1 (ko) * 2014-02-19 2024-12-04 메르크 파텐트 게엠베하 암-표적화된 ｉｌ-12 면역요법
CN107530423B (zh) 2015-01-14 2022-04-05 布里格姆及妇女医院股份有限公司 用抗lap单克隆抗体治疗癌症
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
KR20180107151A (ko) 2016-02-17 2018-10-01 노파르티스 아게 Tgf베타 2 항체
WO2017143451A1 (en) * 2016-02-26 2017-08-31 Western University Anti-cd11d antibodies and uses thereof
FI3365368T3 (fi) * 2016-03-11 2023-06-13 Scholar Rock Inc Tgf-beeta-1:tä sitovia immunoglobuliineja ja niiden käyttö
MX2018014047A (es) 2016-05-17 2019-06-20 Genentech Inc Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
EP3458585A4 (en) * 2016-05-20 2019-10-30 President and Fellows of Harvard College GENE THERAPY PROCEDURES FOR AGE-RELATED ILLNESSES AND SUFFERING
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
WO2018043734A1 (en) * 2016-09-05 2018-03-08 Chugai Seiyaku Kabushiki Kaisha Anti-tgf-beta 1 antibodies and methods of use
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2019045086A1 (ja) * 2017-08-29 2019-03-07 林化成株式会社 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
ES2984919T3 (es) 2017-11-06 2024-10-31 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
WO2020006516A1 (en) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
AU2019377456A1 (en) 2018-11-07 2021-05-27 Merck Sharp & Dohme Llc Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
WO2021142427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. TGFβ INHIBITORS AND USE THEREOF
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
IL309310A (en) * 2021-06-18 2024-02-01 Genzyme Corp Antibody formulations against TGF-beta and their use
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
EP4599088A1 (en) 2022-10-05 2025-08-13 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
EP4676954A1 (en) 2023-03-07 2026-01-14 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
EP1140041A2 (en) 1999-01-05 2001-10-10 University of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1620128A1 (en) 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
EP1646655A2 (en) * 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
EP1765400A2 (en) 2004-06-04 2007-03-28 Genentech, Inc. Method for treating lupus
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties

Also Published As

Publication number Publication date
PT1874818E (pt) 2011-05-05
EA016038B1 (ru) 2012-01-30
WO2006116002A2 (en) 2006-11-02
JP2008538564A (ja) 2008-10-30
US20080050375A1 (en) 2008-02-28
EA200702278A1 (ru) 2008-08-29
ATE505489T1 (de) 2011-04-15
NO20076003L (no) 2008-01-22
DE602006021292D1 (de) 2011-05-26
AU2006240056B2 (en) 2012-02-16
IL186775A0 (en) 2008-02-09
JP5070200B2 (ja) 2012-11-07
CA2607448C (en) 2014-11-18
ES2361269T3 (es) 2011-06-15
EP1874818B1 (en) 2011-04-13
KR20070114220A (ko) 2007-11-29
IL186775A (en) 2013-03-24
US7619069B2 (en) 2009-11-17
SI1874818T1 (sl) 2011-08-31
CA2607448A1 (en) 2006-11-02
BRPI0608376A8 (pt) 2018-10-16
DK1874818T3 (da) 2011-06-14
WO2006116002A3 (en) 2007-02-01
HRP20110334T1 (hr) 2011-06-30
CY1111518T1 (el) 2015-08-05
WO2006116002A9 (en) 2007-07-19
EP1874818A2 (en) 2008-01-09
PL1874818T3 (pl) 2011-09-30
RS51845B (sr) 2012-02-29
AU2006240056A1 (en) 2006-11-02
US8128927B2 (en) 2012-03-06
CN101163719A (zh) 2008-04-16
KR100978684B1 (ko) 2010-08-31
US20100040633A1 (en) 2010-02-18
BRPI0608376A2 (pt) 2010-11-16

Similar Documents

Publication Publication Date Title
UA93201C2 (ru) АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1
TW200709817A (en) Platform antibody compositions
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
MY149630A (en) Antibodies against amyloid-beta peptide
UA100507C2 (ru) Предупреждение и лечение субклинической формы болезней, вызываемых цирковирусом свиней (pcvd)
UA100502C2 (ru) Лечение prdc с применением антигена pcv2
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
NZ594285A (en) USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
MX2009006500A (es) Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3.
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
MX2011000255A (es) Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
TW200733974A (en) Materials and methods for treating chronic fibrotic disease
EA200701820A1 (ru) Применение диосметиновых соединений при лечении и профилактике тромботических патологий
EA200700273A1 (ru) Способ лечения гиперфосфатемии c использованием гидроксикарбоната лантана
UA101961C2 (xx) Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида
WO2010039742A3 (en) Methods to reduce b-helper t cells to treat autoimmune diseases
NZ596218A (en) Bssl antagonists for treatment of inflammatory diseases